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This daily COVID-19 Health Evidence Summary is to signpost DFID and other UK government 
departments to the latest relevant evidence and discourse on COVID-19 to inform and support 
their response. It is a result of 3 hours of work and is not intended to be a comprehensive summary 
of available evidence on COVID-19 but aims to make original documents easily accessible to 
decision makers which, if relevant to them, they should go to before making decisions.   
 
COVID-19 Preparedness and Response 
Publication 
date 
Title/URL Journal/Article 
type 
Summary 
01.05.2020 Cardiovascular 
disease, drug 
therapy and 
mortality in 
Covid-19 
NEJM | Article 
 This study of 8910 patients from 
169 hospitals in Asia, Europe and 
North America confirms previous 
observations suggesting that 
underlying cardiovascular disease 
is associated with an increased 
risk of in-hospital death among 
patients hospitalised with Covid-
19 
 Specifically, factors independently 
associated with an increased risk 
of in-hospital death were age 
greater than 65 years, coronary 
artery disease, heart failure, 
cardiac arrhythmia, chronic 
obstructive pulmonary disease 
and current smoking 
 No increased risk of in-hospital 
death was associated with the 
use of angiotensin-converting-
enzyme(ACE) inhibitors or 
angiotensin-receptor blockers 
(ARBs)– not confirming previous 
concerns  
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01.05.2020 Renin-
Angiotensin-
Aldosterone 
System 
Blockers and 
the risk of 
Covid-19 
NEJM | Article 
 A large population-based case-
control study in the Lombardy 
region of Italy 
 Although use of ACE inhibitors 
and ARBs was more frequent 
among patients with Covid-19 
than among controls because of 
their higher prevalence of 
cardiovascular disease, there was 
no evidence that ACE inhibitors 
or ARBs affected the risk of 
COVID-19 
01.05.2020 Renin-
angiotensin-
aldosterone 
system 
inhibitors and 
risk of Covid-19 
NEJM | Article 
 There was no association 
between any of the 5 common 
classes of antihypertensive 
medications and an increased 
likelihood of a positive Covid-19 
test 
 There was no association of 
these medications with a 
substantial increase in the risk of 
severe illness among patients 
who tested positive 
May 2020 Lost at home: 
the risks and 
challenges for 
internally 
displaced 
children and the 
urgent actions 
needed to 
protect them 
UNICEF | 
Report 
 Children and their families living 
in displacement are “ultra-
vulnerable” to the spread of 
COVID-19 unless quick action is 
taken to protect them and ensure 
response plans consider their 
unique needs. 
04.05.2020 Obesity could 
shift severe 
COVID-19 
disease to 
younger ages 
The Lancet | 
Correspondence 
 In a dataset of 265 patients (58% 
male) admitted to ICU at 6 
university hospitals in the US, 
younger individuals admitted to 
hospital were more likely to be 
obese (significant inverse 
correlation between age and 
BMI).  
 There was no difference by sex 
(p=0.9) 
 Public messaging to younger 
adults, reducing the threshold for 
virus testing in obese individuals, 
and maintain greater vigilance for 
this at-risk population should 
reduce the prevalence of severe 
COVDI-19 disease 
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Indirect impact of COVID-19  
Publication 
date 
Title/URL Journal/Article 
type 
Summary 
01.05.2020 Report 19: 
The potential 
impact of the 
COVID-19 
epidemic on 
HIV, TB and 
malaria in low- 
and middle-
income 
countries 
Imperial 
College 
London | 
Report 
 
 The actions that countries take in the 
coming weeks and months to reduce 
the size of the C19 epidemic will 
have an impact on other major 
health priorities 
 In high burden settings, HIV, TB and 
malaria related deaths over 5y may 
be increased by up to 10%, 20% and 
36% respectively, compared to if 
there were no C19 epidemic 
 Impact could be a loss of life-years 
over 5y similar to the direct impact 
from C19 in places with a high 
burden of malaria and large HIV/TB 
epidemics 
 The greatest impact on HIV could be 
from interruption to ART, which may 
occur during a period of high or 
extremely high health system 
demand 
 The greatest impact on TB could be 
from reductions in timely diagnosis 
and treatment of new cases which 
may result from a long period of C19 
suppression interventions 
 The greatest impact on malaria 
could be from reduced prevention 
activities including interruption of 
planned net campaigns, through all 
phases of the C19 epidemic. 
 Continuing critical prevention 
activities and healthcare services for 
HIV, TB and malaria could reduce 
the broader health impact of the C19 
epidemic, especially in settings with 
a high burden of these diseases. 
01.05.2020 Report 18: 
The potential 
public health 
impact of 
COVID-19 on 
malaria in 
Africa 
Imperial 
College 
London | 
Report 
 
 Approximately 90% of malaria 
deaths occur in SSA 
 Much of the gain made in malaria 
control over the last 10y has been 
due to distribution of LLINs. Many 
SSA countries planned to distribute 
these in 2020. 
 Using C19 and malaria transmission 
models high disruption of all malaria-
control activities could more than 
double the malaria burden in 2020 
compared to the previous year 
depending on how the C19 epidemic 
4 
unfolds and how it interrupts the 
local health system. 
 Results highlight the importance in 
prioritising LLIN distributions before 
or as soon as possible into local C19 
epidemics to mitigate this risk. 
 Continuity of other malaria 
prevention and treatment activities 
where possible will also minimise the 
indirect impact of the C19 epidemic 
27.04.2020 The potential 
impact of 
interruptions to 
HIV services: 
A modelling 
case study for 
South Africa 
medRxiv (not 
peer-reviewed 
| Article 
 Authors model the 5y impact of three 
different potential hypothetical 
scenarios of disruption to HIV 
treatment and prevention services in 
South Africa in order to inform 
planning for service continuity during 
the COVID-19 epidemic. 
 Interrupting the supply of ART for 
40% of those on ART for 3 months 
could cause a number of deaths 
similar to the number anticipated to 
be saved from COVID-19 through 
physical distancing measures. 
 In contrast, if supply and usage of 
ART is maintained, the increase in 
AIDS deaths would be limited to 1% 
over 5y, although there may be an 
increase in new HIV infections if 
there are reductions in VMMC, oral 
PrEP use, and condom availability.  
 Some of the negative impacts of 
service disruption could be reduced 
through policy change e.g. multi-
month ART scripting as now 
recommended where appropriate by 
WHO and PEPFAR 
 Ultimately, ensuring the ART supply 
for individuals currently on treatment 
would minimise excess mortality 
among PLHIV in South Africa, and 
should be a key policy priority 
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Guidelines, Statements & Tools 
Publication 
Date 
Title/URL Source   Description 
05.05.2020 LSHTM COVID-19 
Transmission Model 
(version 1) 
CMMID 
Repository 
Simulate C19 epidemics in 152 
countries, and see how school 
closures, social distancing, 
elderly shielding, self-isolation 
and lockdowns may impact 
cases, hospitalisations and 
deaths. Designed for 
educational purposes not 
medical or policy advice. 
04.05.2020 Community participation is 
crucial in a pandemic 
The Lancet | 
Comment 
Includes a panel of steps to 
community participation in the 
C19 response 
01.05.2020 Statement on the third 
meeting of the International 
Health Regulations (2005) 
Emergency Committee 
regarding the outbreak of 
coronavirus disease 
(COVID-19) 
WHO | 
Statement 
Statement from the third meeting 
(teleconference) of the 
expanded Emergency 
Committee on 30 April 2020 
convened by the WHO DG under 
the IHR (2005) regarding CoVID-
19 
30.04.2020 COVID-19 and the Rights of 
Persons with Disabilities: 
Guidance 
UN Human 
Rights 
  
28.04.2020 COVI-PREG CHUV   International COVID-19 and 
Pregnancy   Registry 
28.04.2020 Accessibility Campaign – 
COVID-19 
International 
Disability 
Alliance 
  Call for PH information and 
communications around COVID-
19 to be fully accessible 
24.04.2020 Handwashing compendium 
for low resource settings: a 
living document (edition 1) 
IDS Sanitation 
Learning Hub 
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Ongoing WHO Country & Technical 
Guidance 
WHO   
Ongoing Rapid guidelines and 
evidence summaries 
NICE   
Ongoing Inter-Agency Standing 
Committee (IASC) 
IASC   
Comments, Editorials, Opinions, Blogs, News 
Publication 
date 
Title/URL Journal | Article 
type 
Author(s) 
04.05.2020 COVID-19 immunity passports and 
vaccination certificates: scientific, 
equitable, and legal challenges 
The Lancet | 
Comment 
Alexandra L. 
Phelan 
04.05.2020 Immunomodulation in COVID-19 The Lancet 
respiratory 
Medicine | 
Comment 
Nicholas E. 
Ingraham et al. 
04.05.2020 Global pledging event raises over €7.4 
billion for COVID-19 research and 
development 
WHO | News 
 
29.04.2020 Show evidence that apps for COVID-19 
contact-tracing are secure and effective  
Nature | Editorial 
 
01.05.2020 Inhibitors of the renin-angiotensin-
aldosterone systems and Covid-19  
NEJM | Editorial   
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Dashboards & Trackers 
Cases & 
deaths: 
Global 
Cases & 
deaths: 
Regional 
Cases & 
deaths: 
Country 
Living 
evidence 
& policy 
maps 
Current 
research 
including 
trials 
  Diagnosti
cs 
  Treatmen
ts 
  Vaccin
es 
WHO 
sitreps 
WHO 
Africa 
Ghana COVID-
NMA 
WHO   FIND 
SARS-
CoV-2 Test 
Tracker 
  Global 
COVID-19 
Clinical 
Trial 
Tracker 
  CEPI 
WHO 
dashboard 
African 
Argumen
ts 
Indonesi
a 
EPPI 
Centre 
WHO 
International 
Clinical Trials 
Registry 
Platform 
(ICTRP) 
  Serology-
based tests 
for COVID-
19 
  US NIH 
registered 
clinical 
trials 
Vaccine 
Centre 
LSHTM 
Johns 
Hopkins 
University 
Europea
n CDC 
Nigeria 
CDC 
Norwegian 
Institute of 
Public 
Health 
Cytel     Solidarity 
trial 
  
WEF 
  Sierra 
Leone 
 Oxford 
C19 
Governme
nt 
Response 
Tracker 
(OxCGRT) 
US NIH     COVID-
19 
Therapeuti
cs 
Accelerator 
  
Our World 
in Data 
  Singapor
e 
  COVID-
evidence 
      
Global 
5050 
  UK   Cochrane       
CEBM, 
University 
of Oxford 
  US   Clinicaltrials.g
ov 
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Humanitari
an Data 
Exchange 
       UKCDR       
Information 
is Beautiful 
              
LSHTM               
HealthMap 
(cases) 
              
The 
Commons 
Project 
              
C19 Resource Hubs 
Global  Region
al & 
Countr
y 
Academi
c 
journals 
& 
Publishe
rs 
Global Health 
Institutes/Centres/Funders/
Other 
Health 
Topics 
  Social 
Sciences 
WHO 
COVID-19 
pandemic  
Africa 
CDC 
The 
Lancet 
LSTM Stop TB 
Partnership 
  SSHAP 
WHO risk 
communicati
on 
African 
Union 
NEJM LSHTM 
 
  IDA 
WHO Q&A Nigeria 
CDC 
Elsevier ICL MRC Centre for Global 
Infectious Disease Analysis  
Global 
Menstrual 
Collective  
  Disability 
and 
inclusion 
WHO Global 
research 
GeoPoll
: SSA 
BMJ ODI SLH: 
Handwashi
ng in low 
  Coregrou
p IDDC 
9 
resource 
settings 
COVID-19 
Solidarity 
Response 
Fund 
Global 
Health 
Networ
k Africa 
Cell 
Press 
Johns Hopkins University 
 
  Rings 
HSG 
Resyst 
Reach 
Wellcome 
UN African 
Acade
my of 
Science
s 
Cochran
e 
resource
s 
Center for Global 
Development 
    Social 
Developme
nt Direct 
C19 blog 
series 
UN Women Africa 
Evidenc
e 
Networ
k 
PLoS CMMID Repository     
UNOCHA   Annals of 
Internal 
Medicine 
Norwegian Institute of Public 
Health 
    
UNHCR     Oxford Centre for Evidence-
based Medicine 
    
UNICEF      HEART     
UNESCO   Wiley 
Health 
Economi
cs 
 UKRI     
UN WFP   Pre-
prints 
medRxiv 
and 
bioRxiv 
 Evidence Aid     
GOARN           
10 
EPI-WIN           
World Bank           
COVID-19 
Narratives by 
David 
Nabarro 
          
Reliefweb           
Humanitarian 
OpenStreetM
ap Team 
          
Global 
Partnership 
for 
Sustainable 
Development 
Data 
          
WorldPop           
Flowminder           
COVID-END           
Premise 
COVID-19 
Global 
Impact Study 
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Online learning & events 
Date Title/URL Online 
learning/event 
Duration Lead 
7-28 May 
2020 
Virtual Evidence 
Weeks 
5 sessions 1h 30 International Initiative 
for Impact Evaluation 
(3ie) 
Tuesdays at 
1700 CEST 
(Geneva 
time) & 
Thursdays 
0830 CEST 
(Geneva 
time) 
COVID-19 Open 
online brief with Dr 
David Nabarro 
Event 1h 4SD 
30.04.2020 Professor Chris 
Whitty’s Gresham 
lecture on COVID-19 
Event 1h 20 Gresham College 
Available 
now 
Emerging respiratory 
viruses, including 
COVID-19: methods 
for detection, 
prevention, response 
and control 
Online learning 3 hours WHO 
Available 
now 
Responding to 
COVID-19: Real-time 
training for the 
coronavirus disease 
outbreak 
Online learning Multiple 
self-paced 
course 
WHO 
25 May 
2020 
COVID-19: Tackling 
the Novel 
Coronavirus 
Online learning 3 weeks | 4 
hours 
weekly 
study 
FutureLearn 
LSHTM/UK PHRST 
20 April 
2020 
COVID-19 
Diagnostics and 
Testing 
Online learning 3 weeks | 3 
hours 
FutureLearn 
FIND/LSHTM/ASLM 
12 
weekly 
study 
6 April 2020 COVID-19 Critical 
Care: Understanding 
and Application 
Online learning 5 weeks | 1 
hour 
weekly 
study 
FutureLearn University 
of Edinburgh & Royal 
College of Physicians 
of Edinburgh  
Available 
now 
COVID-19 supporting 
online courses 
Online learning Multiple 
self-paced 
course 
BMJ Learning 
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Rapid review methodology 
The rapid daily search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa”) OR (“equity” OR “equities”) OR (“poverty”), restricted to 
articles published in the previous 2 to 3 days, in English. This is complemented by a search of the homepage of 
the following high-impact global health journals: The Lancet journals, New England Journal of Medicine, Nature, 
JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ Global Health, the PLoS journals and a Twitter 
search of their Twitter pages. A search also of preprints from bioRxiv and medRxiv. Please note that papers that 
have not been peer-reviewed are highlighted in red. All primary research papers that relate to the primary and 
secondary impacts of the COVID-19 response in LMICs, and disease control and health system responses are 
included. Articles related to tackling the secondary impacts on other sectors are not included. Additional 
commentaries, opinions, and commissioned pieces are selected based on relevance. 
The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
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About this report 
This daily COVID-19 health evidence summary (HES) is based on 3 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before 
making decisions. The HES are not intended to replace medical or professional advice and the researcher or the 
K4D consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES 
alone. K4D services are provided by a consortium of leading organisations working in international development, 
led by the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds 
Nuffield Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), 
University of Birmingham International Development Department (IDD) and the University of Manchester 
Humanitarian and Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Department for 
International Development (DFID) and its partners in support of pro-poor programmes. 
It is licensed for non-commercial purposes only. K4D cannot be held responsible for 
errors, omissions or any consequences arising from the use of information contained in 
this health evidence summary. Any views and opinions expressed do not necessarily 
reflect those of DFID, K4D or any other contributing organisation.  
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